Talk:Methoxetamine

This is the talk page for discussing improvements to the Methoxetamine article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Pharmacology Start‑class Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Start‑class Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Low	This article has been rated as Low-importance on the project's importance scale.

Psychoactive and Recreational Drugs (defunct)

This article is within the scope of WikiProject Psychoactive and Recreational Drugs, a project which is currently considered to be defunct.Psychoactive and Recreational DrugsWikipedia:WikiProject Psychoactive and Recreational DrugsTemplate:WikiProject Psychoactive and Recreational DrugsPsychoactive and Recreational Drugs articles

Designer drug

How can one effectively source the claim that methoxetamine is a designer drug? This wikipedia page (with the - dubious anyway, apparently - definition at Designer drugs) is claiming that methoxetamine was "created (or marketed, if they had already existed) to get around existing drug laws"? One could (if to do so didn't seem both irresponsible and possibly unencyclopaedic) link to a website selling the chemical, but then the website selling the chemical probably wouldn't make it clear for what purpose the chemical was created (or marketed). If one cannot source it, perhaps the claim should be removed, and the page should just say that methoxetamine is a "chemcial of the arylcyclohexylamine class". But then, I think we all know that it probably is a designer drug, but I'm not sure that's good enough to warrant inclusion of that claim: our deduction that it is being marketed to get around existing drug laws smells somewhat of original research to me. So I'll add 'citation needed', and seek others' views on this... GoVaLe2 (talk) 11:21, 24 September 2010 (UTC)[reply]

Don't be pedantic. There's no mention of this chemical in scientific literature. It appeared out of nowhere on vendor web sites which openly refer to it as a replacement for ketamine. It's clearly a designer drug... what do you want, vials of it to come with designer labels like jeans? —Preceding unsigned comment added by 68.225.88.31 (talk) 03:02, 18 January 2011 (UTC)[reply]

Ironically enough, it does come with designer labels on the packaging to signify authenticity, they are small rectangular holographic stickers that say METHOXETAMINE TM, and are only present on "official" batches.--Valerophenone (talk) 23:18, 12 February 2011 (UTC)[reply]

The Lednicer paper says nothing about MXE, or any related arylcyclohexylamines behaving as opioid pro-drugs, where did that come from? It is my suspicion that vendors repeatedly edit this page to insert false information about MXE's rumored opioidergic effects in order to boost sales. Editors should be aware of this.

Substance of Abuse

I would suggest that categorisation as such is a matter of subjective opinion.

Since no one understands the mechanism by which ketamine causes cystitis it is reckless to suggest this ketamine-derivative does not cause bladder damage. This article is perpetuating a potentially dangerous myth since both ketamine and methoxetamine are clearly heavily abused drugs all around the world. There is not enough research on methoxetamine to suggest it does not damage the bladder. The only article on Pubmed is not freely available. (Cavebloke (talk) 14:46, 3 December 2011 (UTC))[reply]

Nobody ever said "does not cause." It says "lessons the risk" which is almost certainly true as the dose is lower. The fact that no instances of bladder toxicity have been reported does not confirm this fact and only time will tell, but I think saying there is lessoned risk is a reasonable assumption, in any case that is what the creator "M." thinks.

Since the creator of Methoxetamine has not performed any toxicity testing and has reported no safety data for the drug I do not believe he is qualified to comment on direct tissue-specific toxicity in the bladder (I believe anecdotally that his background is Chemistry and not Toxicology). Since this is a blackmarket drug with no control over dosage I think there are dangerous implications to suggesting this drug lessens the risk to the bladder. In my opinion, this appears to be a commercial move by the creator/manufaturers of Methoxetamine who want the many global ketamine users with bladder problems to switch to Methoxetamine. I have edited the wiki to remove the statement on cystitis because the citations used were not relevant to the bladder and contained no pertinent information on cystitis. I hope you will all agree this is the safest thing to do under these circumstances. Please suggest a reference which supports the bladder safety of this drug if you disagree. (Cavebloke (talk) 10:39, 8 December 2011 (UTC))[reply]

To my knowledge, there is no such reference. Two pubmed articles now exist and both indicate that further verification is needed to assess whether MXE is more "bladder-friendly" than ketamine. This is not surprising, given the paucity of clinical data regarding MXE toxicity (after all, the two sources I've linked only present a total four clinical cases). Pmillerrhodes ^Talk_Contrib 05:55, 3 January 2012 (UTC)[reply]

I've updated the article and hopefully phrased this ok. Let me know if you think it could be better. SmartSE (talk) 21:46, 23 January 2012 (UTC)[reply]

If MXE was designed to be used as a grey-market recreational drug, you couldn't really say using it to get high is ab-use, as this is the drugs intended purpose... 98.213.75.168 (talk) 22:48, 13 December 2011 (UTC)[reply]

Most (all?) nations restrict recreational use of chemicals, so any personal use (of this drug) would be considered abuse by them.MartinezMD (talk) 23:00, 13 December 2011 (UTC)[reply]

By definition, using mxe recreationally is not ab-use, as recreational use is its intended purpose. Abuse "to use wrongly or improperly; misuse: to abuse one's authority." — Preceding unsigned comment added by 98.213.75.168 (talk) 20:16, 14 December 2011 (UTC)[reply]

But people wouldn't end up in hospital if you didn't abuse it would they.... SmartSE (talk) 21:46, 23 January 2012 (UTC)[reply]

Yes they might, e.g. if a user were to take a carefully measured anesthetic dose and then be found unconscious by someone unaware of the drug and its properties this could be mistakenly considered an overdose and would result in an unnecessary hospitalization. This is often the case, actually.

Swiss case report

I've removed this source because it states that the patient had "a history of multiple drug abuse, psychosis, depression, and attention-deficit hyperactivity disorder" and that "his medications were bupropion (150 mg/day), aripiprazole (15 mg/day), and chlorprothixene (80 mg/day)." which I don't think makes it acceptable to use as a reference, since we can't be sure the hospitalisation wasn't caused by an interaction between drugs. They'd also injected MDMA two days prior to it as well. WP:MEDRS tells us to be wary of primary sources like this one and we already have better sources for the more general fact that people have been hospitalised. I've also rephrased a bit to hopefully make it clearer that nobody really knows anything about its toxicity. SmartSE (talk) 23:15, 26 January 2012 (UTC)[reply]

Roflcoptr

Is this drug the same as Roflcoptr, which is a "party drug" (although what I've read is mostly causing hallucinations, panic attacks and involuntary defecation) currently pretty wide spread, mainly in the UK? Vivo (talk) 10:25, 29 January 2012 (UTC)[reply]

It is - see [1]. I had previously included it, but just notice someone removed it without explanation. I'll replace it. SmartSE (talk) 11:48, 10 February 2012 (UTC)[reply]

Legality

I think it is presumptive to say that MXE is definitively covered by the Federal Analog Act due to being substantially similar to PCP. Legal search engines Westlaw and LexisNexis return no hits for methoxetamine, indicating that there has yet to be any US case involving the substance. It is well established in the relatively scant case law involving the Act that the prosecution has the burden of proving the 'substantially similar' prong of the test in U.S.C. § 802(32)(A)(i) and must also prove that the substance in question does not meet the exception in U.S.C. § 802(32)(C)(iv), which exempts substances "not intended for human consumption." While perhaps arguable from a scientific standpoint, is purely speculative to claim that MXE is a PCP analog for the purposes of the Act, so I don't think Testem's current version warrants inclusion as is. It should also be noted that MXE is not specifically scheduled federally or in any state, though such a point might be uncitable as it is trying to prove a negative. Postvegan (talk) 01:58, 10 February 2012 (UTC) — Preceding unsigned comment added by Postvegan (talk • contribs) 01:54, 10 February 2012 (UTC)[reply]

I agree - there were previously reports that mephedrone was illegal under the analogue act, but the more recent coverage of 'bath salts' in the US suggests that they are not. I'll also remove the Australia info since it's original research to interpret the primary source in that way. SmartSE (talk) 11:52, 10 February 2012 (UTC)[reply]

It isn't original research, nor an ambiguous interpretation. The "research" is in the document, I am simply restating it and how it relates to methoxetamine.Testem (talk) 16:37, 18 February 2012 (UTC)[reply]

Exactly - you are using it to reference something which the source doesn't actually say - a perfect example of OR. No reliable sources say it is legal in Aus, so we shouldn't either. SmartSE (talk) 17:53, 18 February 2012 (UTC)[reply]

Fair enough. I think it's a shame we can't use the original source, but so be it. Is there any way we can link to the original data, perhaps adding my wording now there is another source to corroborate it? — Preceding unsigned comment added by Testem (talk • contribs) 16:30, 20 February 2012 (UTC)[reply]

What do you mean by "now there is another source to corroborate it"? SmartSE (talk) 16:59, 20 February 2012 (UTC)[reply]

Prosecutors have tried to argue that methylone and mephedrone are methcathinone analogs for the purpose of the Act in at least one case, see U.S. v Sullivan, 2011 WL 3957425, though I'm not sure what became of that case i.e. whether the argument was successful. Now the DEA has used its emergency scheduling powers to schedule the substituted cathinones -http://www.deadiversion.usdoj.gov/fed_regs/rules/2011/fr0908.htm - so there is no longer a need to use the Analog Act for those substances. The point is that no case has dealt with MXE, and it not scheduled anywhere. I don't know if we have to lose the entire legality section though, I just though Testem's version was too strongly worded. Postvegan (talk) 21:15, 10 February 2012 (UTC)[reply]

Thanks for that info, but I was only using that as an example to demonstrate that the legality of substances like this is a bit of a grey area, particularly when analog acts are involved. Testem left me a note asking what is required to include information about its legal status. I would like us to at the very least, have primary sources which directly mention methoxetamine. Whilst we can search acts and legal databases and see that it isn't included / no prosecutions have been made, that is original research which isn't allowed - we have to interpret those sources to be able to write something in the article. Even in the UK where most of the coverage so far has been, we need to be careful with how we phrase it. There is now a good source we can use to say it isn't in the MoDA, but that doesn't make it legal in all situations - see the info about 'plant food' in Mephedrone#Legal_status. We can't include anything like that here yet, but it demonstrates that we need to be cautious. SmartSE (talk) 10:05, 13 February 2012 (UTC)[reply]

Antidepressant properties

The information regarding the (potential) antidepressant properties is, at the very least, poorly sourced (see WP:RSMED). I'm removing it. I haven't thoroughly scanned the literature regarding ketamine's antidepressant properties, but at least one review article refers to ketamine as a model for future drug development: "...using ketamine as a starting point to explore improved therapeutics for MDD (Major Depressive Disorder) can stimulate the continuous development and testing of new fast-acting antidepressants displaying increased selectivity. For instance, initial results with speciﬁc drugs that have fewer side effects than ketamine, such as NR2B antagonists, are promising."^[1] I'm not sure that ketamine itself is being considered as a acceptable antidepressant. -Pmillerrhodes ^Talk_Contrib (sorry, forgot to sign)

^ Machado-Vieira, R (2009 Aug). "Ketamine and the next generation of antidepressants with a rapid onset of action". Pharmacology & therapeutics. 123 (2): 143–50. PMID 19397926. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

Good call - I agree that it wasn't appropriate sourcing. SmartSE (talk) 13:40, 18 February 2012 (UTC)[reply]

[1] Machado-Vieira, R (2009 Aug). "Ketamine and the next generation of antidepressants with a rapid onset of action". Pharmacology & therapeutics. 123 (2): 143–50. PMID 19397926. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)

[1]